Nimodipine_product_DataBase

Bioactivity	Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders[1].
Target	dihydropyridine calcium
Invitro	Nimodipine (1.5~150 μg/ml; 15 minutes; B16a and W256 cells) results in a dose-dependent inhibition of B16a and W256 tumor-cell-induced platelet aggregation. Nimodipine is also inhibitory in a homologous system[3].
In Vivo	Nimodipine (0.2 µg/µl, intrathecal administration) prevents subarachnoid hemorrhage-associated cerebral vasospasm by prophylactic continuous intrathecal administration[2].Nimodipine(0.1~80 mg/kg; p.o.) results in a significant dose-dependent inhibition of spontaneous metastasis[3]. Animal Model:
Name	Nimodipine
CAS	66085-59-4
Formula	C21H26N2O7
Molar Mass	418.44
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Reference	[1]. Langley, M.S., et al. Nimodipine. Drugs 37, 669–699 (1989). [2]. Marbacher S, et al. Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo. Intensive Care Med. 2008;34(5):932-938. [3]. Honn KV, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984;2(1):61-72.

PeptideDB